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Chronic HIV-1 infection is characterized by systemic inflammation, disruption of T lymphocyte homeostasis, and immune deregulation. It is widely accepted that chronic inflammation in HIV-1 patients is mainly due to translocation of intestinal microbes and/or their products from the gastrointestinal tract into the systemic circulation (1, 2) . Normally, the intestinal mucosa serves as a barrier to microbes and their products. The gut barrier consists of three major components: (a) biological and microbial barriers, which are responsible for colonization resistance and regulation of the host immune response; (b) the physical barrier, which consists of gut epithelial cells and is maintained by tight junctions; and (c) the immune barrier, which includes various immune factors, immune cells, and gut-associated lymphoid tissues and mediates protection from microbial invasion (3) . All of these barriers are rapidly altered in response to HIV-1 infection. HIV-1-associated changes include the dysregulation of gut flora (4), increased epithelial cell apoptosis (5), altered tight junction expression (6), depletion of intestinal CD4 + T cells, especially Th17 cells (7) , and increased proinflammatory cytokines. Consequently, this barrier damage allows for microbial evasion, further driving systemic inflammation and promoting HIV-1 progression.
Innate lymphoid cells: key players in gut barrier function
Innate lymphoid cells (ILCs) represent a recently recognized family of immune cells that have morphology and cytokine profiles similar to those of T cell lymphocytes, but lack rearranged antigen receptors. Within the past few years, three different ILC populations have been characterized in both mice and humans, including group 1 ILCs, group 2 ILCs, and group 3 ILCs (ILC3s) (8) . Despite the relatively small size of these populations compared with T cells, ILC3s are enriched in lymphoid tissues and gut mucosal areas. Moreover, these cells have been shown to play essential roles in mucosal homeostasis by preventing pathogen infection and promoting tissue repair. ILC3s can produce IL-17 and IL-2 upon IL-1β and IL-23 stimulation and are the major producers of IL-22, which is essential for the gut barrier function in the intestine and associated lymphoid tissues (9) . Previous studies have shown that naive ILC3-or IL-22-deficient mice have altered gut flora, reduced expression of tight junction proteins, mucins, and antimicrobial peptides, and increased rates of epithelial cell apoptosis (9, 10) . Additionally, ILC3s can regulate adaptive immune cell responses through the expression of GM-CSF (11), MHCII (12) , and lymphotoxin (13) . The impaired gut barrier function and low-grade systemic and intestinal inflammation in ILC3-deficient mice result in persistent translocation and systemic dissemination of gut flora (14) as well as an increased susceptibility to pathogen infection and inflammation (14) (15) (16) (17) (18) .
Disruption of ILC3s after HIV-1 infection
Recent studies have shown that the number of ILC3s and production of IL-22 are reduced in the intestines of humans and nonhuman primates after HIV-1 or SIV infection, respectively (19, 20) . However, due to the lack of a robust animal model, the causation and the underlying mechanism that link ILC3 depletion and HIV-1 pathogenesis are poorly understood. In this issue, Zhang and colleagues confirmed that ILC3s are depleted in both blood and gut tissues of HIV-1-infected patients and that this depletion correlates with HIV-1 disease progression (21) . The authors developed a technique to further investigate how the number of ILC3s may influence HIV-1 pathogenesis. Specifically, human ILC3s were transferred into experimental murine models and suc- The The resolution of these issues will help determine whether strategies aimed to modulate ILC3 responses have therapeutic potential to benefit patients with chronic HIV-1.
